Outcomes of adult‐to‐adult living donor liver transplantation in 321 recipients

Hideaki Uchiyama, Ken Shirabe, Koichi Kimura, Tomoharu Yoshizumi, Toru Ikegami, Norifumi Harimoto, Yoshihiko Maehara – 26 November 2015 – We conducted a retrospective investigation in order to clarify whether selecting the type of liver graft had an impact on outcomes of adult‐to‐adult living donor liver transplantation (AALDLT). Data from the medical records of the donors and the recipients of 321 consecutive cases of AALDLT performed between April 2004 and March 2014 were retrospectively analyzed.

Ex vivo evaluation of 4 different viscoelastic assays for detecting moderate to severe coagulopathy during liver transplantation

Ezeldeen Abuelkasem, Michael A. Mazzeffi, Shu Yang Lu, Raymond M. Planinsic, Tetsuro Sakai, Kenichi A. Tanaka – 26 November 2015 – Prolonged prothrombin time (PT) and its ratio are routinely used for the assessment of candidates for liver transplantation (LT), but intraoperative coagulation management of transfusion is hindered by its long turnaround time.

Biliary complications after living donor hepatectomy: A first report from India

Viniyendra Pamecha, Kishore Gurumoorthy Subramanya Bharathy, Senthil Kumar, Shridhar Vasantrao Sasturkar, Piyush Kumar Sinha – 26 November 2015 – Biliary complications after donor hepatectomy can result in significant morbidity. We herein present our experience of donor hepatectomy, highlighting surgical techniques that prevent complications. Data were reviewed from a prospectively maintained database of all donors who underwent hepatectomy from April 2011 to April 2015. Standard operative technique as described was followed in all patients.

Down‐regulation of the cyclin‐dependent kinase inhibitor p57 is mediated by Jab1/Csn5 in hepatocarcinogenesis

Hui Guo, Li Jing, Yangzi Cheng, Vassilis Atsaves, Yi Lv, Tao Wu, Rujuan Su, Yamin Zhang, Ronghua Zhang, Wenbin Liu, George Z. Rassidakis, Yongchang Wei, Kejun Nan, Francois X. Claret – 25 November 2015 – Down‐regulation of p57 (KIP2) cyclin‐dependent kinase inhibitors accelerates the growth and invasion of hepatocellular carcinoma (HCC), suggesting that p57 may play an important role in liver carcinogenesis. However, the mechanism or oncogenic signal leading to p57 down‐regulation in HCC remains to be determined.

Reply

Annabel Blasi, Virginia Hernandez‐Gea, Juan Carlos Reverter, Juan Carlos Garcia‐Pagán – 25 November 2015

The rs2294918 E434K variant modulates patatin‐like phospholipase domain‐containing 3 expression and liver damage

Benedetta Donati, Benedetta Maria Motta, Piero Pingitore, Marica Meroni, Alessandro Pietrelli, Anna Alisi, Salvatore Petta, Chao Xing, Paola Dongiovanni, Benedetta del Menico, Raffaela Rametta, Rosellina Margherita Mancina, Sara Badiali, Anna Ludovica Fracanzani, Antonio Craxì, Silvia Fargion, Valerio Nobili, Stefano Romeo, Luca Valenti – 25 November 2015 – The patatin‐like phosholipase domain‐containing 3 (PNPLA3) rs738409 polymorphism (I148M) is a major determinant of hepatic fat and predisposes to the full spectrum of liver damage in nonalcoholic fatty liver disease (NAFLD).

Subscribe to